Biotech Stability Programs Could Benefit From Reanalysis Of Early Batches
Executive Summary
The importance of retaining sample material from development and early-stage clinical batch production for later evaluation is being emphasized by FDA and industry experts in exploring ways to improve biopharmaceutical stability programs